<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564772</url>
  </required_header>
  <id_info>
    <org_study_id>78958</org_study_id>
    <secondary_id>Allina IRB No. 2366-1</secondary_id>
    <secondary_id>Prism Research No. 714</secondary_id>
    <secondary_id>FDA IND No. 78958</secondary_id>
    <nct_id>NCT00564772</nct_id>
  </id_info>
  <brief_title>Raltegravir Kaletra Pharmacokinetics</brief_title>
  <acronym>RAL-KAL</acronym>
  <official_title>An Open-Label, Sequential, 3-Period Study to Evaluate Pharmacokinetics of Coadministered Raltegravir (Isentress) and Lopinavir-Ritonavir (Kaletra) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allina Hospitals and Clinics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allina Hospitals and Clinics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, 3-period, fixed sequence study in young, healthy, male and female
      subjects of the pharmacokinetic interaction between raltegravir and Kaletra.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label, 3-period, fixed sequence study in young, healthy, male and female
      subjects. The initial cohort, to be studied simultaneously, will be 15 subjects with
      intention to collect complete data from 12 subjects. Replacements will be subsequently
      enrolled if necessary. Subjects will be reimbursed.

      The periods will be

        -  Period 1: Raltegravir (RAL) 400 mg q12h for 4 days (7 doses of RAL).

        -  Period 2: Kaletra 200 mg 2 pills bid for 10 days (19 doses of Kaletra).

        -  Period 3: both regimens for 4 days (7 doses of both drugs). All morning doses will be
           observed at Prism Research, Inc. Evening doses will be distributed each morning. 12 hour
           PK studies will be done on the last day of each period. Specimens will be obtained 0,
           0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours after the morning dose of the last dosing
           day of each period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>drug levels of lopinavir, ritonavir, raltegravir</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects dosed the same</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir, lopinavir, ritonavir</intervention_name>
    <description>4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Isentress</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male or female, age 18-55.

          -  Anti-HIV, anti-HCV, HBsAg negative.

          -  Normal history and physical at screening.

          -  Normal complete blood count, creatinine and ALT at screening.

          -  Negative urine pregnancy test at screening.

          -  BMI 18-30.

        Exclusion Criteria:

          -  Donated blood in the month before Day 1.

          -  Participated in another research study in the month before Day 1.

          -  Tobacco use in the 3 months before Day 1, unwillingness to avoid tobacco use during
             the study.

          -  Use of any illegal drug in the year before Day 1, positive drug screen for an illegal
             drug at screening.

          -  Unwillingness to restrict coffee use to 6 or fewer cups of coffee during the study.

          -  Unwillingness on the part of fertile female subjects to be abstinent or to use two
             effective birth control methods, one of which is a barrier method, for any vaginal
             intercourse.

          -  Unwillingness to avoid use of any prescribed medication during the study

          -  Allergy to RAL, lopinavir or ritonavir.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank S Rhame, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allina Hospitals &amp; Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Research Inc</name>
      <address>
        <city>St Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2007</study_first_submitted>
  <study_first_submitted_qc>November 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2007</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Frank Rhame</name_title>
    <organization>Allina Health System</organization>
  </responsible_party>
  <keyword>raltegravir</keyword>
  <keyword>lopinavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

